Premium
Oncological impact of hypothyroidism and levothyroxine supplementation following hemithyroidectomy in patients with papillary thyroid carcinoma
Author(s) -
Ahn Dongbin,
Lee Gil J.,
Sohn Jin H.,
Jeon Jae H.
Publication year - 2020
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.26075
Subject(s) - levothyroxine , medicine , thyroid carcinoma , univariate analysis , hormone , thyroid , thyroid function , thyroid stimulating hormone , urology , gastroenterology , surgery , multivariate analysis
Background We aimed to evaluate the oncological impact of hypothyroidism and levothyroxine (LT) supplementation after hemithyroidectomy in patients with papillary thyroid carcinoma (PTC). Methods We retrospectively examined 401 patients who underwent hemithyroidectomy for classic PTC and who were postoperatively followed‐up with ≥3 thyroid function measurements for ≥24 months. Results During 77.4 months of follow‐up, 268/401 patients (66.8%) developed hypothyroidism and 19/401 patients (4.7%) showed recurrence. Recurrence rates did not differ between the euthyroidism and hypothyroidism development groups. Recurrence rates were significantly lower in the LT group than in the no‐LT group, although mean postoperative thyroid‐stimulating hormone (TSH) levels were not different between the two groups. Univariate and multivariate analysis showed that tumors sized >1 cm and lack of LT supplementation were significantly associated with recurrence. Conclusions Postoperative hypothyroidism development was not a risk factor for PTC recurrence after hemithyroidectomy. Nevertheless, LT supplementation reduced recurrence risk without suppressing TSH.